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Treatment Selections using Risk-Benefit Profiles Based on Data from
Comparative Randomized Clinical Trials with Multiple Endpoints
Brian Claggett, Lu Tian, Davide Castagno, and L. J. Wei∗
Abstract
In a longitudinal, randomized clinical study to compare a new treatment with a
control, oftentimes each study subject may experience any of several distinct outcomes
during the study period, which collectively define the “risk-benefit” profile. To assess
the treatment difference, it is desirable to utilize the entirety of such outcome infor-
mation. The times to these events, however, may not be observed completely due to
competing risks. The standard analyses based on the time to the first event, or in-
dividual component analyses with respect to each event time, are not ideal. In this
paper, we classify each patient’s risk-benefit profile, by considering all event times dur-
ing follow-up, into several clinically meaningful ordinal categories. We first show how
to make inferences for the treatment difference in a two-sample setting with incomplete
categorical data. To bring the study results to the individual patient’s bedside, we then
present a systematic procedure to identify patients who would benefit from a specific
treatment using baseline covariate information. Specifically, we split the data set into
two independent pieces. Using the data from the first piece, we build, as a function of
the baseline covariates, a scoring system for assessing treatment differences, with the
final model(s) chosen via a cross-validation process. With the data from the second
piece, we non-parametrically estimate the treatment differences across a range of the
resulting scores. A desirable subgroup of patients can then be identified with respect
to the size of the treatment difference for treatment selection. The proposal is illus-
trated with the data from a clinical trial to evaluate a beta-blocker for treating chronic
heart failure patients, for whom it was unclear whether known risks of beta-blocking
agents would outweigh anticipated benefits (Beta-Blocker Evaluation of Survival Trial
Investigators, 2001).
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1. INTRODUCTION
Consider a randomized, comparative clinical trial in which a treatment is assessed against a
control with respect to their risk-benefit profiles. For each study patient, the outcome vari-
ables include a set of distinct event time observations reflecting such profiles during the study
period. Often these event times cannot be observed completely due to the presence of com-
peting risks. For example, to investigate if the beta-blocking drug, bucindolol, would benefit
patients with advanced chronic heart failure (HF), a clinical trial, Beta-Blocker Evaluation of
Survival Trial (BEST), was conducted (Beta-Blocker Evaluation of Survival Trial Investiga-
tors, 2001). There were 2708 patients enrolled and followed for an average of two years. The
primary endpoint of the study was the patient’s overall survival time. For patients in the
two treatment arms, the Kaplan-Meier estimates for survival are given in Figure 1(a) with
a p-value of 0.10 based on the standard two-sample logrank test, favoring the beta-blocker
but not reaching statistical significance. Although mortality is an important endpoint, the
treatment benefit evaluation should also include morbidity for chronic heart failure patients.
One important morbidity measure is the time to hospitalization, especially due to worsening
HF. Unfortunately such event times may be “informatively” censored, for example, by the
patient’s survival time. To avoid such competing-risk problems, one may consider the time
to the first event among all competing events of interest as the endpoint. For example, for
the BEST study, the competing events are death and HF or non-HF hospitalization. In
Figure 1(b), we present the corresponding KM estimates for such an event time analysis.
With this endpoint, the beta-blocker is not statistically significantly better than the control,
with a p-value of 0.14. Note that this type of endpoint does not fully reflect the disease
burden or progression over the entire duration of the patient’s follow-up, since only one
event at most is utilized per patient. In Table 1, we show the frequencies of the occurrences
of these component endpoints from the study patients whose data were obtained from the
National Heart, Lung and Blood Institute. Note that mortality may be classified as either
cardiovascular (CV) or non-CV related, in which case it may be expected that an effective
1
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Figure 1: Kaplan-Meier estimates from BEST trial. Solid and dashed lines represent control
and treated groups, respectively.
beta-blocker would lower the rate of events classified into the former category, but have no
impact on the latter category. In general, it is not expected that a beta-blocker would have
any beneficial effect on non-CV outcomes. In addition, part of the undesirable side effects
of beta-blockers may be captured by non-CV outcomes (for example, non-CV related death
or non-HF hospitalization). It is also important to note that a patient may have multiple
events during the study follow-up reflecting the disease progression. The times to all these
events contain valuable clinical information for comparing two groups with respect to overall
disease burden and should not be ignored for the analysis.
Table 1: Numbers of Patients Experiencing Specific Clinical Endpoints in Control and Treat-
ment Groups in BEST
Outcome Control Treated
Death 448 411
CV Death 388 342
Non-CV Death 60 69
Any Hosp. 874 829
HF Hosp. 568 476
Non-HF Hosp. 634 619
Total Patients 1353 1354
∗CV=Cardiovascular, ∗HF=Heart Failure
For a typical cardiovascular study like BEST with multiple event time observations,
2
Hosted by The Berkeley Electronic Press
conventional secondary analyses for risk-benefit assessments are often conducted with each
type of endpoint (for example, the time to HF hospitalization). The conclusions of such
component analyses can be misleading due to competing risks. Moreover, because component
events are analyzed separately rather than jointly, they cannot provide a global, clinically
meaningful evaluation of the new treatment. To this end, there are novel procedures for
handling multiple event time observations proposed, for example, by Andersen and Gill
(1982), Wei et al. (1989), and Lin et al. (2000). In the presence of competing risks, however,
the above procedures or their modifications are not entirely satisfactory for assessing the
treatment’s overall risk and benefit (Li and Lagakos, 1998; Ghosh and Lin, 2003; Pocock
et al., 2012).
In this article, we create an ordinal categorical outcome variable which reflects the in-
dividual patient’s morbidity, including toxicity, and mortality over the entire study period
for evaluating the treatments. Such a classification system may be constructed by a panel
of clinical experts who can classify various possible patient outcome patterns into categories
(e.g., “improved”, “stabilized”, or “worsened”, or finer ordinal subcategories). For example,
for the BEST study, with guidance from our cardiologist co-author, we classified patient
response, using five ordinal categories, based on the disease burden during 18 months of
follow-up. Category 1 is assigned if the patient has experienced neither death nor any hospi-
talization prior to the time of evaluation. The patient is classified as Category 2 if he or she
is alive and has experienced only non-HF hospitalization (reflecting potential toxicity). Cat-
egory 3 denotes patients who are alive, but have experienced HF-hospitalization (reflecting
lack of efficacy). Category 4 is assigned if the patient has died from non-CV related causes.
Finally, Category 5 refers to those patients who suffered CV-related death. Note that often,
study patients might not have their entire clinical history, until their time of death or at 18
months after randomization, available due to non-informative, or administrative, censoring.
In the paper, we first present methods for analyzing such ordinal, possibly incomplete,
data in a two-sample overall comparison setting. Note that making patient-specific decisions
3
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based on estimated population-averaged effects can lead to sub-optimal patient care (Kent
and Hayward, 2007). A positive (negative or neutral) trial based on some overall assessment
does not mean that every future patient should (should not) be treated by the new treat-
ment. To bring the clinical trial results to the patient’s bedside, we may utilize the patient’s
characteristics to perform personalized or stratified medicine. Unfortunately, the typical ad
hoc subgroup analysis of clinical studies is not credible (Wang et al., 2007). Moreover, such
subgroup analysis is often conducted by investigating the effect of only a single predictor
at a time and therefore may not be effective, from a risk-benefit perspective, in identifying
patients who would benefit from the new treatment. Here, we present a systematic approach
to create a scoring system using the patient’s multiple baseline covariates and utilize this sys-
tem to stratify the patients for evaluation with respect to the ordinal categorical outcomes.
More specifically, to avoid overly optimistic model selections, we first divide the data set
into two pieces. The two pieces may be obtained by splitting the entire data set randomly
or sequentially, dividing the data according to the order in which patients entered into the
study. With the first piece, a cross-validation procedure is utilized to select the best scoring
system among all of the competing models of interest for ordinal categorical data. We then
use the second piece (the so-called holdout sample) to make inferences about the treatment
differences over a range of the score selected from the first stage. All proposals are illustrated
with the data from the BEST study.
When there is a single baseline covariate involved, Bonetti et al. (2000), Song and Pepe
(2004), and Bonetti and Gelber (2004) have proposed novel statistical procedures for iden-
tifying a subgroup of patients who would benefit from the new treatment with respect to
a single outcome. A recent paper by Janes et al. (2011), based on previous work by Pepe
(2004), Huang et al. (2007), and Pepe et al. (2008), provides practical guidelines for assessing
the performance of individual markers for the purposes of treatment selection. By incorpo-
rating more than one baseline covariate, our approach is similar in spirit to Cai et al. (2011)
and Li et al. (2011). However, they used the data from the entire study to create a scoring
4
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system by fitting a prespecified model without involving model evaluation or variable selec-
tion and then used the same data set to make inferences for either the treatment difference
with respect to a single outcome or for risk predictions for a single treatment group only.
Note that Chuang-Stein et al. (1991) utilized an ordinal categorical outcome with individual
patients’ subjective weightings of the categories for a summary measure for personalized
treatment selection. Their novel approach is quite different from our proposal.
2. TWO-SAMPLE ASSESSMENT OF TREATMENT EFFECT USING
INCOMPLETE CATEGORICAL OBSERVATIONS
For the jth patient in the ith treatment group, (j = 1, . . . , ni; i = 1, 2), let Tij be the time
to the first occurrence of a terminal event from among the competing risks of interest. Note
that Tij may be infinite if there is no terminal event. Let Cij be the independent censoring
variable for Tij. Let Xij = min(Tij, Cij) and ∆ij is an indicator variable, which is one if
Tij ≤ Cij. Let Gi be the survival function of the censoring variable Cij. For each study
patient, assume that based on his/her entire morbidity and mortality endpoint information
up to time t0, where pr(Cij > t0) > 0 (i = 1, 2), one can classify the outcome  as one of K
ordered categories. In general, we make no assumptions about how the patient’s classification
may change over time. That is, the patient’s classification may improve or worsen during
the follow-up time. Note that we do not require traditional “competing risks” methods to
account for informative censoring because we include such informative events in the definition
of the patient outcome categories.
Let piik be the probability of  = k with treatment i, (i = 1, 2; k = 1, . . . , K). Let
ij, j = 1, . . . , ni, be the response for the jth patient in the ith group. Noting that a patient’s
outcome status is observable only when min(Tij, t0) ≤ Cij, the cell probabilities piik can be
consistently estimated, via inverse probability of censoring weighting, by
pˆiik =
ni∑
j=1
wijI(ij = k)
Gˆi(Xij ∧ t0)
/
ni∑
j=1
wij
Gˆi(Xij ∧ t0)
, (1)
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where I(·) is the indicator function, wij = I(Xij ≤ t0)∆ij + I(Xij > t0), and Gˆi(·) is
the Kaplan-Meier estimator for Gi(·) (Li et al., 2011). In order to compare two treatment
groups with such ordinal categorical outcomes, one may compare the cumulative distributions
γik =
∑k
l=1 piil, i = 1, 2; k = 1, . . . , K. Let Γk = γ2k − γ1k and let γˆik be the corresponding
estimators via pˆiik. Note that each value Γk, k = 1, . . . , K − 1, may be interpreted as the
risk difference with respect to a binomial outcome in which “success” is defined by a patient
experiencing ( ≤ k). To make inferences on the difference of these two distribution functions,
we may use bootstrapping or perturbation-resampling methods (Uno et al., 2007). Details
are provided in the Appendix.
For the data from BEST, let t0 = 18 months. Using the five ordinal categories described
in the Introduction, Table 2 displays the profiles of the estimated distribution functions for
each treatment group γik and the differences Γk. For each level k, the estimated distribution
function for the beta-blocker group (γˆ2k) is larger than for the control group (γˆ1k), indicating
that the beta-blocker group is numerically better than its control counterpart with respect
to each outcome.
Table 2: Estimated distribution functions for control and treated groups with BEST data
with t0 = 18 months
Control (γˆ1) Treated (γˆ2) Contrast (Γˆ)
Outcome Category n pr( ≤ k) n pr( ≤ k) Est SE
1 397 0.37 442 0.41 0.04 0.03
2 174 0.54 224 0.62 0.08 0.02
3 251 0.77 190 0.80 0.03 0.02
4 35 0.80 39 0.83 0.03 0.02
5 246 1.00 211 1.00 - -
(censored) 250 - 248 - - -
To compare two groups with respect to ordinal categorical outcomes, a conventional way
to summarize the treatment difference is to use an ordinal regression model. Let τij = 1 for
patients in treated group and 0 otherwise, then this model is:
g(pr(ij ≤ k)) = αk − βτij, (2)
6
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where g(·) is a known, increasing function and αk and β are unknown parameters. Here
β can be interpreted as an overall measure of the treatment difference even if the model is
not correctly specified. Under such parameterization, for the present case, a negative value
for β corresponds to an reduction in overall “risk” associated with treatment. With cen-
sored observations, the treatment difference β can be estimated by maximizing the standard
weighted multinomial log-likelihood function:
∑
ij
wij
Gˆi(Xij ∧ t0)
[
K∑
k=1
I(ij = k)log{g−1(αk − βτij)− g−1(αk−1 − βτij)}], (3)
where α0 = −∞, αK = ∞, and standard error estimates can be obtained via perturbation-
resampling methods. Under mild conditions, the estimator βˆ from the above model converges
to a finite constant β as n→∞ even when the model is not correctly specified (Zheng et al.,
2006; Uno et al., 2007; Li et al., 2011). For the data from BEST, when g(·) is the logit
function, βˆ is −0.227 with a standard error estimate of 0.072. This indicates that the beta-
blocker indeed reduces the disease burden. Details are given in the Appendix.
Rather than using a parametric summary of the treatment difference, an intuitively in-
terpretable, nonparametric summary measure is the so-called general risk difference, which
has been studied extensively as an extension of the simple risk difference for ordinal data (Si-
monoff et al., 1986; Agresti, 1990; Edwardes, 1995; Edwardes and Baltzan, 2000; Lui, 2002).
In this setting, the general risk difference, which is closely related to Wilcoxon’s rank-sum
statistic, is D = pr(1 > 2)− pr(1 < 2), where i, i = 1, 2, is a patient response randomly
chosen from treatment group i, with positive values suggesting that treated patients (i = 2)
are generally more likely to be in a “healthier” state rather than an “unhealthier” state, com-
pared to their control counterparts (i = 1). Here 1 and 2 are independent. A consistent
estimator for D then is Dˆ =
∑K
k=2 pˆi1,kγˆ2,k−1 − pˆi2,kγˆ1,k−1. The standard error estimate can
be obtained via bootstrap (Simonoff et al., 1986) or perturbation-resmapling methods as in
Uno et al. (2007). For the data from the BEST trial, Dˆ = 0.069 with standard error estimate
of 0.023. Using this model-free summary of the treatment difference, the beta-blocker again
7
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appears better than the control. Details are given in the Appendix.
3. CONSTRUCTION AND SELECTION OF A PATIENT-LEVEL
STRATIFICATION SYSTEM
Suppose that Ui is the baseline covariate vector for a subject randomly chosen from the ith
treatment group (i = 1, 2). Our goal is to make inference about the treatment difference
based on 1 and 2, conditional on U1 = U2 = u, any given value in the support of the
covariate vector. Ideally, one would estimate this conditional treatment difference via a
nonparametric procedure. However, if the dimension of U is greater than one, it seems
difficult, if not impossible, to do so. A practical alternative is to model the relationship
between the treatment difference and U parametrically and then validate the selected model.
To avoid an “overly optimistic” personalized prediction model, we split the data set into two
pieces, say, part A and part B. With the data from part A, we build various candidate models
for the conditional treatment differences and evaluate them via a cross-validation procedure.
This results in a univariate scoring system with which to stratify the patients, which we refer
to as a treatment selection score. In this section, we present the first step using the part A
data, i.e., the construction and selection of the scoring system, and in the next section, we
show how to make inferences about the treatment differences based on the selected scoring
system using the part B data. It is important to note that, to validate the scoring system,
we need a model-free summary measure for the treatment difference. For the present case
with the ordinal categorical response discussed in Section 2, the treatment contrast,
D(u) = pr(1 > 2|U1 = U2 = u)− pr(1 < 2|U1 = U2 = u), (4)
is model-free and heuristically interpretable. Note also that to obtain a coherent prediction
system, it is preferable to use the same treatment contrast measure for model building,
selection and validation.
8
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3.1 Creating Treatment Difference Scoring Systems
There are numerous ways to estimate (4) parametrically. For instance, one can model the
ordinal categorical response via two separate ordinal regression models, that is, for each
treatment i and conditional on Uij:
gi(γik(Uij)) = αik − β′iZij, i = 1, 2; j = 1, . . . , ni (5)
where γik(Uij) = pr(i ≤ k|Uij), Zij is a function of Uij, gi(·) is a known monotone increasing
function, and αik and βi are unknown parameters. It follows that a parametric estimate
Dˆ(u) for D(u) is given by
Dˆ(u) =
K∑
k=1
pˆi1,k(u)γˆ2,k−1(u)− pˆi2,k(u)γˆ1,k−1(u) (6)
where estimated probabilities γˆik(u) are obtained from the fitted models (5) and pˆii,k(u) =
γˆi,k(u)− γˆi,k−1(u), with γˆi,0 = 0, i = 1, 2.
Alternatively, we may use a single model
g(γik(Uij)) = αk − β′Zij − τij(θ′Z∗ij), (7)
where Z∗ij = (1, Z
′
ij)
′, and α, β, and θ are unknown parameters. The resulting probability
estimates γˆik(u) may similarly be used to estimate Dˆ(u) via (6).
Models (5) may be fitted to the data by applying inverse probability of censoring weights
and maximizing the group-specific weighted multinomial log-likelihood functions
ni∑
j=1
wij
Gˆi(Xij ∧ t0)
[
K∑
k=1
I(ij = k)log{g−1(αik − β′iZij)− g−1(αi,k−1 − β′iZij)}], (8)
9
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where α0 = −∞, αK =∞, i = 1, 2. For model (7), the log-likelihood function is
∑
ij
wij
Gˆi(Xij ∧ t0)
[
K∑
k=1
I(ij = k)log{g−1(αk−β′Zij−τij(θ′Z∗ij))−g−1(αk−1−β′Zij−τij(θ
′
Z∗ij)}],
(9)
Under some mild conditions, the resulting estimators (αˆ, βˆ, θˆ) from the above models con-
verge to a finite constant vector as n → ∞ even when the model (5) or (7) is not correctly
specified (Uno et al., 2007). Note that one may repeatedly utilize (5) or (7) along with (8)
or (9) using various Z and g(·) via, for instance, a stepwise regression procedure, to obtain
final estimates γˆik(U) and Dˆ(U).
3.2 Evaluation and Selection of a Final Model for Stratification
To choose the “best” stratification system from among many possible candidates obtained
via the process described in Section 3.1, we use a cross-validation procedure. Specifically, we
split the data into two parts randomly. We fit the data from the first part with each of the
models of interest, then use the data from the second part to evaluate them via an intuitively
interpretable, model-free criterion. Note that unlike the one-sample risk prediction problem,
most standard evaluation criteria based on individual prediction errors (e.g., with respect to
the L1 or L2 norm) are not applicable here because each study patient was only assigned to
either the treatment or control, not both. However, a “goodness of fit” measure using the
concordance between the true treatment difference D(u) in (4) and the rank of the parametric
score Dˆ(u), say, C = Cov{H(Dˆ(U)), D(U)}, can be estimated consistently under the current
setting, where H(·) is the distribution function of Dˆ(U) and the covariance is with respect
to the random covariate vector U . Here, C can be estimated by
Ĉ =
∫ 1
0
(1− q)
[∑n1
j=1
∑n2
j′=1
[I(1j>2j′ )−I(1j<2j′ )]I{Hˆ(Dˆ1j)>q,Hˆ(Dˆ2j′ )>q}
{Gˆ1(X1j∧t0)/w1j}{Gˆ2(X2j′∧t0)/w2j′}∑n1
j=1
∑n2
j′=1
I{Hˆ(Dˆ1j)>q,Hˆ(Dˆ2j′ )>q}
{Gˆ1(X1j∧t0)/w1j}{Gˆ2(X2j′∧t0)/w2j′}
− Dˆ
]
dq, (10)
10
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where Hˆ(·) is the empirical cumulative distribution function of Dˆ(U) and Dˆij = Dˆ(Uij). The
justification of the consistency of (10) can be derived using similar arguments to those given
by Zhao et al. (2012). Now, since the variances of D(U) and H(Dˆ(U)) are independent of
the fitted model, the correlation ρ corresponding to C can be estimated up to a common
constant across all candidate models. Therefore, to quantify the improvement of, say, Model
I relative to Model II, we may take the ratio of the resulting covariance estimates Ĉ1/Ĉ2
to estimate the ratio of the two corresponding correlation coefficients ρˆ1/ρˆ2, to guide model
selection.
We use a repeated random cross-validation procedure, in each iteration randomly dividing
this part A data set into two mutually exclusive subsets, B and E, the “model building set”
and “evaluation set”, respectively. For each model building set and for a given link function
and variable selection procedure, we can construct a model, using only data in B to obtain
Dˆ(·) via (6), then compute all Dˆ(Uij), for all Uij in E. We repeatedly split the training
data set M times. For each m, and for each modeling procedure, we obtain an estimate of
the concordance Ĉ(m). Lastly, we average these estimates over m = 1, ...,M to obtain final
estimates Ĉ. The modeling procedure which yields the largest cross-validated C values will
be used for the construction of our final working model. We then refit the entire part A data
set with this specific modeling procedure in order to construct the final score.
3.3 Construction and Selection of Scoring Systems Using the BEST Data Set
We first split the data set into parts A and B, using the first 900 (33%) patients entering
the study as part A and using the remaining patients as part B. In this sense, we mimic the
traditional prediction process, using current data to predict the future outcomes of patients.
Note that Shao (1993) presents theoretical justifications for the preference of a relatively large
holdout sample, and a comparatively smaller sample size devoted to “model construction”.
Within part A data, 123, 60, 86, 9, and 84 patients in the control group were classified into
categories 1 through 5, respectively, after 18 months of followup. The corresponding counts
for the treatment group were 148, 74, 52, 13, and 68 patients, respectively. The numbers of
11
http://biostats.bepress.com/harvardbiostat/paper153
censored patients in part A were 94 and 89 in the control and treatment groups, respectively.
Here the covariate vector U consists of 16 clinically relevant covariates from Table 1
of Castagno et al. (2010). These baseline variables are: age, sex, left ventricular ejection
fraction (LVEF), estimated glomerular filtration rate adjusted for body surface area (eGFR),
systolic blood pressure (SBP), class of heart failure (Class III vs. Class IV), obesity (Body
mass index (BMI) > 30 vs. BMI ≤ 30), resting heart rate, smoking status (ever vs. never),
history of hypertension, history of diabetes, ischemic heart failure etiology, presence of atrial
fibrillation at baseline, and race (white vs. non-white). As in Castagno et al. (2010), we
used 3 indicator variables to discretize eGFR values into 4 categories, with cut-points of 45,
60, and 75.
Models (5) and (7) were utilized with the logit and complementary log-log links, g(p) =
log( p
1−p), and g(p) = log(−log(1−p)), respectively. For each of type of model, first we let Z
be the vector of the above 16 covariates. We then consider a stepwise regression procedure
with the weighted likelihood function as the objective function and an Akaike information
criterion (AIC) as the criterion for covariate inclusion/exclusion. For each type of model
(5) or (7), we started with all covariates (and first order interactions with the treatment
indicator for (7)), and successively added/eliminated terms until no more covariates could
be added/removed without subsequently increasing the AIC. For illustration, a total of eight
modeling procedures were considered in our analysis. To evaluate these models, we used a
repeated random cross validation procedure with 80% of the part A data used for model
building and 20% for evaluation for each iteration of the procedure with M = 25 iterations.
In Table 3, we present these modeling procedures along with their relative concordance
value, based on Cˆ with the modeling approach of separate logistic regression models with
no variable selection as the reference model.
The model building procedure found to provide the most overall discriminatory ability
was the one which models each treatment group separately, using the complementary log-log
link, and performs AIC-based variable selection. This procedure is marked with ∗ in Table
12
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3. We then used this model building procedure to fit the entire part A data. The resulting
model is given in Table 4. We note that six variables were eliminated from both models, six
variables were retained in one model only, and four variables were retained in both models.
Table 3: Model building procedures with average cross-validated concordance values
Separate/Single Models Link Var. Selection Ĉ Ratio
Separate logit None (ref)
Separate logit AIC 2.01
Separate c-log-log None 1.62
Separate c-log-log AIC 2.17∗
Single logit None 0.99
Single logit AIC 1.91
Single c-log-log None 1.61
Single c-log-log AIC 0.90
Table 4: Regression coefficients for the final working models using BEST training data with
log(−log) link function
Control Group Treated Group
Covariate β1 β2
LVEF -0.018 -0.034
I(eGFR>75) -0.237 -0.489
I(eGFR>45) -0.673 -0.753
SBP -0.012 -
Class IV Heart Failure - 0.843
I(BMI>30) 0.218 0.212
Heart Rate - -0.008
History of hypertension 0.213 -
History of diabetes 0.359 -
Atrial Fibrillation 0.263 -
4. MAKING INFERENCES ABOUT THE TREATMENT DIFFERENCES OVER A
RANGE OF SCORES USING THE HOLDOUT SAMPLE
Let dˆ(u) be the observed score, obtained from the part A data set, for a patient in the part
B data set with covariates u. In this section, using the data from Part B, we make inferences
about the general risk difference E(s) = pr(1 > 2|dˆ(u) = s)− pr(1 < 2|dˆ(u) = s) and the
cumulative risk differences Γk(s) = pr(2 ≤ k|dˆ(u) = s)− pr(1 ≤ k|dˆ(u) = s), k = 1, . . . , K,
13
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where i is outcome of a random patient in treatment group i from a future population
identical to the part B data. Rather than using a parametric estimate for these contrast
measures, we use a nonparametric kernel functional estimation procedure conditional on
the treatment selection score. To this end, let the conditional cell probabilities for the
ordinal response ij be denoted by piik(s) and cumulative probabilities by γik(s), i = 1, 2; j =
1, . . . , n∗i ; k = 1, . . . , K. Here n
∗
i is the sample size in the ith group in the part B data
set. Let pˆiik(s) and γˆik(s) be their corresponding nonparametric kernel estimators. Let
Yijk = I(ij = k), k = 1, . . . , K. The kernel estimators for piik(s) and γik(s) are
pˆiik(s) =

n∗i∑
j
wijYijk
Gˆi(Xij ∧ t0)
Khi(Vij − s)
 /

n∗i∑
j
wij
Gˆi(Xij ∧ t0)
Khi(Vij − s)
 , (11)
and γˆik(s) =
∑k
l=1 pˆiil(s), i = 1, 2; k = 1, . . . , K, where Vij = dˆ(Uij), wij = I(Xij ≤
t0)∆ij + I(Xij > t0), Gˆi(·) is the Kaplan-Meier estimator of Gi(·) from the part B data,
Khi(s) = K(s/hi)/hi, K(·) is a smooth symmetric kernel with finite support and hi is a
smoothing parameter. The resulting estimator for E(s) is Eˆ(s) =
∑K
k=1 pˆi1,k(s)γˆ2,k−1(s) −
pˆi2,k(s)γˆ1,k−1(s). When hi = O(n∗−vi ), 1/5 < v < 1/2, it follows from a similar argument by
Li et al. (2011) that pˆiik(s) converges to piik(s) uniformly over the interval s ∈ S, where S is
an interval contained properly in the support of dˆ(U). Consequently, when hi is of the same
order as above, for a fixed s, the distribution (n∗1h1 + n
∗
2h2)
1/2{Γˆk(s)− Γk(s)}, k = 1, . . . , K
converges in distribution to a normal with mean 0 and covariance σk(s) as n
∗
i →∞, i = 1, 2.
Similarly, the distribution (n∗1h1+n
∗
2h2)
1/2{Eˆ(s)−E(s)} converges in distribution to a normal
with mean 0 and variance σ(s) as n∗i → ∞, i = 1, 2. To approximate the distributions
above, we use a perturbation-resampling method, which is similar to ‘wild bootstrapping’
(Wu, 1986; Mammen, 1993) and has been successfully implemented in many estimation
problems (Lin et al., 1993; Park and Wei, 2003; Cai et al., 2010). In addition, (1 − α)
simultaneous confidence bands for E(s) and Γk(s) over the pre-specified interval S can be
obtained accordingly. Details are provided in the Appendix.
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As with any nonparametric estimation problem, it is important that we choose appropri-
ate smoothing parameters in order to make inference about the treatment differences. Here,
we use a L-fold cross-validation procedure to choose the smoothing parameter hˆi which max-
imizes a weighted cross-validated multinomial log-likelihood, as in Li et al. (2011). Specifi-
cally, we may randomly divide the entire data set into L mutually exclusive, approximately
equally sized subsets. For any fixed values of hi and (i, k), we can estimate piik(s) using all
observations except for those contained in the same subset as the jth subject, which yields
the estimator pˆii(−j)k(s). The cross-validated log-likelihood, adjusted for censoring, is
∑
Vij∈S
wij
Gˆi(Xij ∧ t0)
{
K∑
k=1
Yijklog(pˆii(−j)k(Vij))}. (12)
Let hˆi be a maximizer of (12). As in Li et al. (2011), hˆi is of the order n
∗−1/5. To ensure
the bias of the estimator is asymptotically negligible and that the above large-sample ap-
proximation is valid, however, we slightly undersmooth the data and let the final smoothing
parameter be h˜i = hˆi × n∗−ξi where ξ is a small positive number less than 0.3.
4.1 Making Inference About Treatment Differences using the BEST Data Set
Next, we apply the final scoring system derived from the part A data set to the patients
in the part B data set mentioned in Section 3.3. In Figure 2 below, we show the empirical
cumulative distribution function of the scores in the part B data set. The vertical line
indicates dˆ(u) = 0, and we note that 75% of the scores fall to the right of this line, indicating
an anticipated treatment benefit for a majority of patients. For all kernel estimators, we let
K(·) be the standard Epanechnikov kernel, with the smoothing parameters chosen as the
maximizers of (12), then multiplied by n∗−0.05i .
The resulting estimates of the patient-specific treatment differences Eˆ(s), with 0.95 point-
wise and simultaneous confidence interval estimates, are displayed in Figure 3. Using the
final score derived from the model in Table 4 over the range s ∈ (−0.26, 0.40), we find
Eˆ(s) > 0 for s > −0.11 and Eˆ(s) < 0 for s < −0.11. The point and interval estimates
15
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Figure 2: Distribution of treatment selection scores dˆ(u) for BEST patients in the holdout
sample.
displayed in Figure 3 are quite informative for identifying subgroups of patients who would
benefit from the beta-blocker with various desired levels of treatment differences.
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Figure 3: Estimated BEST treatment effect Eˆ(s) using treatment selection score presented
in Table 4. Solid curve represents point estimates, with 0.95 pointwise and simultaneous
confidence intervals denoted by dashed lines and shaded region, respectively.
In Figure 4, we show the corresponding treatment differences with respect to the cumu-
lative outcome probabilities γik(·). Note that each value Γk(s) allows for the estimation of
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the treatment contrast with respect to a different composite outcome. For example, Γ1(s)
refers to the effect of treatment on the composite outcome “any hospitalization or death”.
It can be seen that Γˆ1(s) > 0 for s > 0.02 and Γˆ1(s) < 0 for s < 0.02, indicating that our
score is also informative for identifying patients would experience “treatment success” with
respect to this outcome as well. Furthermore, using Γˆ2, patients with scores > 0.05 and
> 0.24 are found to experience significant treatment benefits (via the 95% confidence inter-
vals and bands, respectively) with respect to the desirable outcome ( ≤ 2) (alive with no
HF hospitalization). Finally, we note that the estimated effect of treatment with respect to
death, Γˆ3(s), is relatively constant with a (non-significant) risk reduction of approximately
2% across the scores.
5. CONCLUSIONS
The proposed procedures can be applied to any study with multiple endpoints which re-
flect a patient’s risk-benefit profile. For example, a longitudinal trial may collect repeated
measurements for an endpoint over time. The standard analysis, for example, via GEE
techniques (Liang and Zeger, 1986) provides a treatment comparison using an average mean
difference of a response variable during the study follow-up. Such a contrast may not provide
a clinically interpretable summary, particularly when the temporal profile of such repeated
measures should be considered for the outcome. One may instead classify the repeated mea-
sure profile for each individual patient into several clinically meaningful categories, such as
those presented in this paper for evaluating the treatments risk(s) and benefit(s) together.
For ordinal categorical outcomes, one may give each stratum a weight and create a single
univariate outcome as the final endpoint. However, the estimates for the treatment difference
for each category are quite informative for treatment selections. To avoid post-hoc subgroup
analysis, we highly recommend pre-specifying a systematic procedure for identifying patients
who would benefit from the new treatment in the study protocol or its statistical analysis
plan.
17
http://biostats.bepress.com/harvardbiostat/paper153
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4
-0
.2
0.
0
0.
2
! = 0
vsss
R
is
k 
D
iff
er
en
ce
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4
-0
.2
0.
0
0.
2
! = 1
vsss
R
is
k 
D
iff
er
en
ce
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4
-0
.2
0.
0
0.
2
! = 2
vsss
R
is
k 
D
iff
er
en
ce
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4
-0
.2
0.
0
0.
2
! = 3
vsss
R
is
k 
D
iff
er
en
ce
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4
-0
.2
0.
0
0.
2
! = 4
R
is
k 
D
iff
er
en
ce
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4
-0
.2
0.
0
0.
2
! ! 0
vsss
R
is
k 
D
iff
er
en
ce
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4
-0
.2
0.
0
0.
2
! ! 1
vsss
R
is
k 
D
iff
er
en
ce
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4
-0
.2
0.
0
0.
2
! ! 2
vsss
R
is
k 
D
iff
er
en
ce
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4
-0
.2
0.
0
0.
2
! ! 3
vsss
R
is
k 
D
iff
er
en
ce
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4
0.
0
1.
0
2.
0
Distribution of Risk Scores
D
en
si
ty
! !1
! ! 2
! ! 3
! ! 4
White text to block out axis 
White text to block out axis 
White text to block out axis 
Sc re 
Figure 4: BEST target treatment differences (treated minus untreated) using treatment se-
lection score presented in Table 4. Solid curve represents point estimates, with 0.95 pointwise
and simultaneous confidence intervals denoted by dashed lines and shaded region, respec-
tively.
When there are more than two treatments available for selection, one may create a scoring
system such as a “risk score”, for example, based on the data from the control or standard
care arm. Then we may use the holdout sample to estimate the treatment effectiveness
nonparametrically over the selected score. For comparing two treatment groups only, we
recommend using the treatment difference score rather than the risk score from the control
only.
If the disease progression is not reversible, i.e., a patient’s classification cannot improve
over time, one may utilize more information from a censored observation rather than using
18
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the inverse probability of censoring weighting scheme. For example, to estimate {piik, i =
1, 2; k = 1, . . . , K}, if the ordinal response of the patient is l at the censored time, then the
contribution to the weighted likelihood from this patient is
∑
k≥l piik.
For comparing scoring systems constructed for the treatment difference, we use a con-
cordance measure between the observed and expected treatment differences. More research
is needed to explore if other measures, which may be more intuitively interpretable, can be
used for model evaluation and selection. Moreover, it is important to consider a parsimo-
nious model as the final candidate even if it is not the optimal one based on the selection
criteria. The application of a parsimonious scoring system can have more clinical utility than
an optimal, but complex, system. For ordinal categorical outcomes, we use the general risk
difference D, the net treatment improvement rate, to estimate the treatment contrast. It
would be interesting to consider other measures for quantifying the contrast, reflecting the
size of the treatment difference.
APPENDIX
For all inference using large sample approximations, we employ perturbation-resampling
procedures using 1000 realizations from the standard exponential distribution. Details are
provided below.
Construction of Confidence Intervals for Two-Sample Inference
Let {Bij : i = 1, 2; j = 1, . . . , ni} be independent random samples from a strictly positive
distribution with mean and variance equal to one. Let pi∗ik be the perturbed version of pˆiik
with
pi∗ik =
{∑
j
BijwijYijk
Gˆ∗j(Xij ∧ t0)
}
/
{∑
j
Bijwij
Gˆ∗i (Xij ∧ t0)
}
, (A.1)
and γ∗ik =
∑k
l=1 pi
∗
il. Here, Gˆ
∗
i (·) is the perturbed estimator for the survival function Gi(·)
Gˆ∗i (t) = exp
[
−
ni∑
j=1
∫ t
0
Bijd{I(Cij ≤ u ∧Xij)}∑ni
l=1BilI(Xil ≥ u)
]
. (A.2)
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Let β∗ be the maximizer of the perturbed version of the weighted log-likelihood function
in (3): ∑
ij
Bijwij
Gˆ∗i (Xij ∧ t0)
[
K∑
k=1
Yijklog{g−1(αk − βτij)− g−1(αk−1 − βτij)}]. (A.3)
The limiting distribution, conditional on the data, of
(n1 + n2)
1/2{β∗ − βˆ}, (A.4)
is normal with mean 0 and variance σˆ2b , which is a consistent estimator of σ
2
b , the variance
associated with the distribution (n1 + n2)
1/2{βˆ − β}. Thus, the empirical variance of the
perturbed estimates β∗ can be used to estimate the standard error associated with βˆ (Zheng
et al., 2006; Uno et al., 2007; Li et al., 2011).
Denote Γ∗ = γ∗2 − γ∗1 , where γ∗i = {γ∗i1, · · · , γ∗iK}′. Using the arguments by Cai et al.
(2010), the limiting distribution, conditional on the target data set, of
(n∗1 + n
∗
2)
1/2{Γ∗ − Γˆ}, (A.5)
is multivariate normal with mean zero and covariance matrix Σˆ which is a consistent es-
timator of Σ, the covariance matrix associated with the distribution (n∗1 + n
∗
2)
1/2{Γˆ − Γ}.
The resulting sample covariance matrix based on those perturbed estimates Γ∗, say, Σ˜, is a
consistent estimator of Σ. A two-sided confidence interval for the two-sample risk difference
Γk is then given by
Γˆk ± z(1−α/2)(n∗1h1 + n∗2h2)−1/2σ˜k, (A.6)
where σ˜2k is the kth diagonal element of Σ˜. Furthermore, one may use a similar approach
for making inference on Dˆ by perturbed D∗ =
∑K
k=2 pi
∗
1,kγ
∗
2,k−1 − pi∗2,kγ∗1,k−1.
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Construction of Confidence Intervals and Bands for Stratified Inference
For personalized medicine, we let pi∗ik(s) be the perturbed version of pˆiik(s) with pi
∗
ik(s)
=
{∑
j
Bijwij
Gˆ∗j(Xij ∧ t0)
Khi(Vij − s)Yijk
}
/
{∑
j
Bijwij
Gˆ∗i (Xij ∧ t0)
Khi(Vij − s)
}
. (A.7)
and γ∗ik(s) =
∑k
l=1 pi
∗
il(s). Using identical arguments to those above, we denote Γ
∗(s) =
γ∗2(s)− γ∗1(s), where γ∗i (s) = {γ∗i1(s), · · · , γ∗iK(s)}′, and can show that the distribution for
(n∗1h1 + n
∗
2h2)
1/2{Γ∗(s)− Γˆ(s)}, (A.8)
conditional on the observed data is multivariate normal and asymptotically equivalent to
that of (n∗1h1 + n
∗
2h2)
1/2(Γˆ(s)−Γ(s)). Therefore, the point-wise confidence interval for Γ(s)
can be constructed using generated Γ∗(s) as in (A.4).
To construct a (1 − α) simultaneous confidence band for Γk(s) over the pre-specified
interval S, we cannot use the conventional method based on the sup-statistic,
sup
s∈S
σ˜−1k (s)|(n∗1h1 + n∗2h2)1/2{Γˆk(s)− Γk(s)}| (A.9)
due to the fact that as a process in s, (n∗1h1 + n
∗
2h2)
1/2{Γˆk(s) − Γk(s)} does not converge
weakly to a tight process. On the other hand, one may utilize the strong approximation
argument given in Bickel and Rosenblatt (1973) to show that an appropriately transformed
sup of Γˆk(s) − Γk(s) converges to a proper random variable. In practice, to construct a
confidence band, we can first find a critical value bα such that
pr(sup
s∈S
|Γ∗k(s)− Γˆk(s)|/{(n∗1h1 + n∗2h2)−1/2σ˜k(s)} > bα) ≈ α. (A.10)
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Then the confidence band for Γk(s) : s ∈ S is given by
Γˆk(s)± bα(n∗1h1 + n∗2h2)−1/2σ˜k(s). (A.11)
Similar arguments are used for the construction of the confidence band for E(s) : s ∈ S.
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